Claire Scudder
Senior Trial Manager
I have been working in trial management since 2005, primarily on later Phase II and Phase III CTIMPs, within an oncology setting. My current research interests are CTIMPs in paediatric populations.
Recent publications
-
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
Journal article
Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Journal article
Urbonas V. et al, (2019), Annals of Oncology, 30, 317 - 324
-
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Journal article
Iveson TJ. et al, (2018), The Lancet Oncology, 19, 562 - 578
-
Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma
Conference paper
Middleton MR. et al, (2017), Clinical Trials
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Journal article
Kerr RS. et al, (2016), The Lancet Oncology, 17, 1543 - 1557